Teladoc Health, Inc.(TDOC)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,022 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
TDOC Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Teladoc Health, Inc. (TDOC), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores TDOC at 38.2/100 on a 32-signal composite quality model, placing it at rank #2,022 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (19.3) and revenue growth (27.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 32.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Teladoc Health, Inc. reports quarterly revenue of $613.8M, net income of $-63.8M, an operating margin of -10.1%. Top institutional holders of TDOC by reported 13-F value include TENOR CAPITAL MANAGEMENT Co., L.P., D. E. Shaw & Co.,, Context Capital Management,, based on the most recent SEC filings. TDOC trades on the NYSE exchange and files with the SEC under CIK 1477449. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate TDOC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Teladoc Health, Inc. directly from SEC EDGAR. Teladoc Health, Inc.'s 13F Pro composite quality score has ranged between 8 and 51 since 2022, currently 38.2 — a declining long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q1 2026
$613.8M
Net Income
Q1 2026
$-63.8M
Free Cash Flow
Q1 2026
$7.9M
Operating Margin
Q1 2026
-10.1%
ROIC
Q1 2026
-4.6%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
-2.8% YoYNet Income
+9.1% YoYOperating Income
-5.8% YoYEPS (Diluted)
+14.9% YoYTotal Assets
-34.9% YoYTotal Debt
Op. Cash Flow
-15.9% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $2.53B -2.8% | $2.60B +8.1% | $2.41B +18.4% | $2.03B +85.8% | $1.09B +97.7% | $553.3M |
| Net Income | $-200.3M +9.1% | $-220.4M +98.4% | $-13.66B -3085.6% | $-428.8M +11.6% | $-485.1M -390.7% | $-98.9M |
| Operating Income | $-263.0M -5.8% | $-248.6M +98.2% | $-13.65B -5039.9% | $-265.6M +47.5% | $-506.4M -529.5% | $-80.4M |
| EPS (Diluted) | $-1.14 +14.9% | $-1.34 +98.4% | $-84.60 -2998.9% | $-2.73 +49.1% | $-5.36 -288.4% | $-1.38 |
| Total Assets | $2.86B -34.9% | $4.39B +1.1% | $4.35B -75.5% | $17.73B -0.1% | $17.76B +1007.7% | $1.60B |
| Total Debt | — | — | — | $0.00 -100.0% | $42.6M | $0.00 |
| Operating Cash Flow | $294.4M -15.9% | $350.0M +84.9% | $189.3M -2.4% | $194.0M +462.5% | $-53.5M -279.2% | $29.9M |
Get alerted when TDOC's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Teladoc Health, Inc. including:
Top Institutional Holders of TDOC
TENOR CAPITAL MANAGEMENT Co., L.P.
$181.7M188,653,000 shD. E. Shaw & Co., Inc.
$141.1M146,917,000 shContext Capital Management, LLC
$113.1M117,959,000 shRadcliffe Capital Management, L.P.
$110.4M115,750,000 shBALYASNY ASSET MANAGEMENT L.P.
$81.4M84,968,000 shBlackRock, Inc.
$79.6M14,613,556 shVANGUARD PORTFOLIO MANAGEMENT LLC
$67.0M12,295,094 shCAMDEN ASSET MANAGEMENT L P /CA
$59.8M62,641,000 shDeepCurrents Investment Group LLC
$52.7M55,000,000 shOpti Capital Management, LP
$48.0M50,000,000 sh
| Fund | Value | Shares |
|---|---|---|
| TENOR CAPITAL MANAGEMENT Co., L.P. | $181.7M | 188,653,000 |
| D. E. Shaw & Co., Inc. | $141.1M | 146,917,000 |
| Context Capital Management, LLC | $113.1M | 117,959,000 |
| Radcliffe Capital Management, L.P. | $110.4M | 115,750,000 |
| BALYASNY ASSET MANAGEMENT L.P. | $81.4M | 84,968,000 |
| BlackRock, Inc. | $79.6M | 14,613,556 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $67.0M | 12,295,094 |
| CAMDEN ASSET MANAGEMENT L P /CA | $59.8M | 62,641,000 |
| DeepCurrents Investment Group LLC | $52.7M | 55,000,000 |
| Opti Capital Management, LP | $48.0M | 50,000,000 |
More Healthcare Companies
View all Healthcare →Put TDOC on your watchlist
Track score changes the day Teladoc Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is TDOC a good stock to buy?
13F Pro's AI-powered analysis of Teladoc Health, Inc. (TDOC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for TDOC are available on the TDOC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own TDOC?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling TDOC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Teladoc Health, Inc.'s investment landscape.